Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate, vatalanib, and hydroxyurea may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of
tumor cells by blocking blood flow to the tumor. Giving imatinib mesylate and vatalanib
together with hydroxyurea may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate
and vatalanib when given together with hydroxyurea in treating patients with recurrent or
relapsed malignant glioma.